Previsión

No hay datos de analistas disponibles para esta empresa.

Debates en la comunidad

Todavía no hay ninguna discusión sobre este activo.

Iniciar debate

  • CSL continues rally after strong FY26 results and announces share buyback

    CSL reported FY26 total revenue of $15.8bn and an adjusted net profit after tax and depreciation and amortization of $3.1bn, both slightly above revised analyst expectations. The company expects adjusted earnings growth of around 5% for FY27 and announced a new share buyback program of A$1.1bn. Analysts subsequently raised several price targets; UBS, CLSA and Morgan Stanley upgraded their ratings, supported by stronger plasma trends, about $176m in cost savings and greater strategic flexibility following the spin-off of Seqirus. » Más en de.investing.com


  • CSL forecasts return to growth and launches A$1.1bn share buyback - shares at 6.5‑month high

    CSL raised its outlook for fiscal 2027 and now expects currency‑adjusted growth in adjusted net profit after tax of around 5%, well above consensus of about 2%. For fiscal 2026 the company reported revenue of US$15.8bn, adjusted NPATA of US$3.1bn (−2%) and a reported net loss of US$2.6bn after one‑off impairments related to CSL Vifor. CSL also announced a A$1.1bn share buyback program, which lifted the share price by about 5% to A$165.88. » Más en de.investing.com


  • CSL rises 16.4% after results and outlook

    CSL called 2026 a “transition year”, reporting revenue of $15.8 billion (currency‑adjusted -1%) and an adjusted NPAT‑A of $3.1 billion, while a statutory loss of $2.6 billion was caused by $6.0 billion of restructuring and impairments. Investors focused on a strong operating cash flow of $3.5 billion, a new $1.1 billion AUD share buyback program and the outlook for around 5% adjusted NPAT growth in 2027 with largely stable revenue. CSL Behring is expected to return to mid‑single‑digit revenue growth in the medium term, while Vifor, as the biggest drag for 2027, expects revenue to fall by about 25%. The stock jumped 16.4% after the announcement as the market put more weight on the outlook, cash flows and capital returns than on the accounting loss. » Más en de.investing.com


  • CSL reports billion-dollar write-downs and lowers guidance – shares plunge

    Biotech company CSL announces billion-dollar write-downs and lowers its guidance, triggering a sharp share price fall. Investors fear consequences for competition in the mRNA market, and BioNTech is mentioned as a potential beneficiary. » Más en finanzen.net


  • CSL reports 81% profit decline after $1.1bn impairments – shares plunge

    CSL reported a reported net profit decline of 81% to $401m in the first half of 2026 after one-off impairments totaling $1.1bn. Adjusted NPATA rose 7% to $1.9bn on revenue of $8.3bn (+4%). Management confirmed the full-year guidance, announced an increase of the share buyback to $750m and target cost savings of $500–550m by FY2028; the stock fell sharply after the announcement and is trading near its 52-week low. » Más en de.investing.com

En 2026, CSL ya ha pagado 2,48 € en dividendos. El último pago fue en octubre.

Datos financieros

En el último trimestre, CSL tuvo unos ingresos de 6394,25 M € y un beneficio neto de -2571,16 M €

(EUR) junio de 2026
YoY
Ingresos 6394,25 M -
Beneficio bruto 2838,63 M -
Beneficio neto -2571,16 M -
EBITDA 1685,92 M -

Datos fundamentales

Métrica Valor
Capitalización bursátil
56,02 mil M €
Número de acciones
479,88 M
Máximo/mínimo de 52 semanas
129,08 € - 58,10 €
Rentabilidad por dividendo
2,02 %
Dividendos TTM
2,48 €
Beta
0,08
Ratio P/E
-25,36
Ratio PEG
0,14
Ratio P/B
4,34
Ratio P/S
4,09

Perfil de la empresa

CSL Limited investiga, desarrolla, fabrica, comercializa y distribuye productos biofarmacéuticos y afines en Australia, Estados Unidos, Alemania, Reino Unido, Suiza, China e internacionalmente. La empresa opera a través de dos segmentos, CSL Behring y Seqirus. El segmento CSL Behring ofrece terapias con plasma, como productos derivados del plasma y recombinantes para el tratamiento de la inmunodeficiencia, los trastornos hemorrágicos, el angioedema hereditario, el déficit de alfa-1 antitripsina y los trastornos neurológicos. Este segmento también realiza investigación sobre terapias con y sin plasma, y recibe licencias y regalías por la comercialización de propiedad intelectual. El segmento Seqirus fabrica y distribuye productos bioterapéuticos sin plasma, y desarrolla productos relacionados con la gripe. CSL Limited fue fundada en 1916 y tiene su sede en Parkville, Australia.

Nombre
CSL
CEO
Gordon Naylor DipCompSc
Sede Melbourne, vic
Australia
Sitio web
Sector
Salud
Industria
Biotecnología
Salida a bolsa
01/06/1994
Empleados 29.000

Símbolos bursátiles

Bolsa Símbolo
Pnk
CMXHF
Australian Securities Exchange Ltd
CSL.AX
Frankfurt
CSJ.F
Düsseldorf
CSJ.DU
Hamburg
CSJ.HM
SIX
CSL.SW
München
CSJ.MU
🍪

Parqet  usa cookies. Más información